Literature DB >> 11302832

Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.

R Hafner1, J Bethel, H C Standiford, S Follansbee, D L Cohn, R E Polk, L Mole, R Raasch, P Kumar, D Mushatt, G Drusano.   

Abstract

This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between azithromycin and rifabutin in volunteers with or without human immunodeficiency virus infection. Daily dosing with the combination of azithromycin and rifabutin was poorly tolerated, primarily because of gastrointestinal symptoms and neutropenia. No significant pharmacokinetic interactions were found between these drugs.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11302832      PMCID： PMC90510          DOI： 10.1128/AAC.45.5.1572-1577.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA).

Authors: 
Journal:  MMWR Recomm Rep       Date:  1999-08-20

2.  Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease.

Authors:  D E Griffith; B A Brown; R J Wallace
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

Review 3.  Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease.

Authors:  B A Brown; D E Griffith; W Girard; J Levin; R J Wallace
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

4.  Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients.

Authors:  S L Koletar; A J Berry; M H Cynamon; J Jacobson; J S Currier; R R MacGregor; M W Dunne; D J Williams
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

5.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

6.  Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

Authors:  E C Oldfield; W J Fessel; M W Dunne; G Dickinson; M R Wallace; W Byrne; R Chung; K F Wagner; S F Paparello; D B Craig; G Melcher; M Zajdowicz; R F Williams; J W Kelly; M Zelasky; L B Heifets; J D Berman
Journal:  Clin Infect Dis       Date:  1998-03       Impact factor: 9.079

7.  Pharmacokinetics of rifabutin.

Authors:  M H Skinner; M Hsieh; J Torseth; D Pauloin; G Bhatia; S Harkonen; T C Merigan; T F Blaschke
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

Authors:  S D Nightingale; D W Cameron; F M Gordin; P M Sullam; D L Cohn; R E Chaisson; L J Eron; P D Sparti; B Bihari; D L Kaufman
Journal:  N Engl J Med       Date:  1993-09-16       Impact factor: 91.245

9.  Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy.

Authors:  C R Horsburgh; J A Havlik; D A Ellis; E Kennedy; S A Fann; R E Dubois; S E Thompson
Journal:  Am Rev Respir Dis       Date:  1991-09

10.  The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients--a prospective study.

Authors:  D P Chin; A L Reingold; E N Stone; E Vittinghoff; C R Horsburgh; E M Simon; D M Yajko; W K Hadley; S M Ostroff; P C Hopewell
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226
View more
  4 in total

1.  Recurrent neutropenia induced by rifabutin in a renal transplant recipient.

Authors:  Ji Yeun Chang; Eun Gyo Jeong; Ji Hyun Yu; Byung Ha Chung; Chul Woo Yang
Journal:  Korean J Intern Med       Date:  2014-06-27       Impact factor: 2.884

2.  Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers.

Authors:  Christophe Schmitt; Myriam Riek; Katie Winters; Malte Schutz; Susan Grange
Journal:  Arch Drug Inf       Date:  2009-03

3.  Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

Authors:  Stefanie Hennig; Elin M Svensson; Ronald Niebecker; P Bernard Fourie; Marc H Weiner; Stefano Bonora; Charles A Peloquin; Keith Gallicano; Charles Flexner; Alex Pym; Peter Vis; Piero L Olliaro; Helen McIlleron; Mats O Karlsson
Journal:  J Antimicrob Chemother       Date:  2016-01-31       Impact factor: 5.790

4.  Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams.

Authors:  Mathieu S Bolhuis; Prashant N Panday; Arianna D Pranger; Jos G W Kosterink; Jan-Willem C Alffenaar
Journal:  Pharmaceutics       Date:  2011-11-18       Impact factor: 6.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.